• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage publications (all current information on this profile has been aggregated automatically from publisher and metadata sources).
  • Silvia Laura Locatelli, Giuseppa Careddu, +9 authors Carmelo Carlo-Stella
  • Biology, Medicine
  • Clinical cancer research : an official journal of…
  • 2019 (First Publication: 1 February 2019)
  • PURPOSE Tumor-associated macrophages (TAMs) and the hyperactivation of the PI3K/AKT pathway are involved in the pathogenesis of Hodgkin lymphoma and affect disease outcome. Because the δ and γContinue Reading
  • Silvia Laura Locatelli, Giuseppa Careddu, Giuliano Giuseppe Stirparo, Luca Castagna, Armando Santoro, Carmelo Carlo-Stella
  • Chemistry, Medicine
  • Scientific reports
  • 2016 (First Publication: 21 October 2016)
  • PI3K/AKT and RAF/MEK/ERK pathways are constitutively activated in Hodgkin lymphoma (HL) patients, thus representing attractive therapeutic targets. Here we report that the PI3K/ERK dual inhibitorContinue Reading
  • Silvia Laura Locatelli, Roberto Papait, +6 authors Carmelo Carlo-Stella
  • Biology
  • 2014 (First Publication: 6 December 2014)
  • INTRODUCTION: Lenalidomide monotherapy exerts clinical activity in relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL) with better response rate and progression-free survival being recorded inContinue Reading
  • Silvia Laura Locatelli, Giuseppa Careddu, +5 authors Carmelo Carlo-Stella
  • Medicine
  • 2015 (First Publication: 3 December 2015)
  • INTRODUCTION: The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma (HL). Activation of this pathway is critical for transformation andContinue Reading
  • Silvia Laura Locatelli, Francesca Maria Consonni, +6 authors Carmelo Carlo-Stella
  • Medicine
  • 2016 (First Publication: 2 December 2016)
  • INTRODUCTION: Primary refractory and early-relapsed patients with Hodgkin lymphoma (HL) experience poor responses to salvage chemotherapy and dismal long-term disease control. Therefore, theyContinue Reading